Banish

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Banish

Quick Facts

Property Description
Active ingredient Cimetidine
Forms Tablet, Oral Solution, Injectable Solution
Pharmacological class Histamine H2 Receptor Antagonist
General purpose Gastric Acid Reduction
Origin Synthetic Small Molecule

What is Banish and How is it Classified?

The medication Banish is a brand containing the active ingredient Cimetidine, which is classified as a Histamine H2 receptor antagonist, often referred to as an H2 blocker. Cimetidine is a synthetic small molecule drug characterized by its role in controlling and reducing the production of stomach acid. This classification positions Banish as an established antisecretory agent in a therapeutic group recognized for regulating gastric acidity. Its primary differentiation lies in its precise, chemically quantified approach to acid regulation, distinct from other major acid-reducing categories.


What are the Available Forms and Types of Banish?

Banish is a single-ingredient product available in multiple pharmaceutical preparations, most commonly as an oral tablet and an oral solution. The brand's use of an oral solution provides a feature for easier administration and dosage adjustment compared to solid forms. The medicine is broadly marketed for managing general symptoms of acid indigestion, making it a clinically recognized option for relieving discomfort from heartburn. Cimetidine is effective in suppressing acid secretion, and its targeted action provides reliable symptomatic relief for the upper gastrointestinal lining.


What is the General Purpose of Banish?

The overarching purpose of Banish is to act as a powerful gastric acid reducer by specifically inhibiting the chemical signals that trigger acid production in the stomach. The medication achieves this by blocking the H2 receptors on the stomach's parietal cells, thereby reducing the total volume and acidity of gastric fluid. This controlled reduction in acid output is essential for alleviating the discomfort associated with acid indigestion, promoting a less irritating environment in the esophagus and stomach.

What side effects are possible with Banish?

Possible Side Effects and Safety Information

The official safety profile for Banish (Cimetidine) classifies adverse reactions based on their frequency and the physiological systems affected, according to regulatory documents from government authorities.


Adverse Reaction Classification

Adverse effects are documented across various System-Organ Classes (SOCs), including Gastrointestinal Disorders, Nervous System Disorders, Hepatobiliary Disorders, and Blood and Lymphatic System Disorders. Reactions are categorized by frequency, which range from Very Common (e.g., increased plasma creatinine) to Common (e.g., headache, diarrhea, skin rashes).

Less frequent but documented adverse effects classified as Uncommon or Rare may include mental confusion, leukopenia, and cardiac effects such as tachycardia or sinus bradycardia. Serious adverse reactions officially listed in regulatory texts are rare and include Agranulocytosis, Aplastic anemia, Fatal hepatic effects, and severe skin reactions such as Stevens-Johnson syndrome.


Safety Patterns and Constraints

The official labeling specifies certain safety patterns related to the timing of exposure. Increases in plasma creatinine are typically observed during the first week of treatment. Conversely, effects like gynecomastia have been reported in patients treated for one month or longer.

Population-Specific Safety: Regulatory documents note that elderly patients and individuals with renal or hepatic impairment have a documented increased risk for Central Nervous System (CNS) adverse reactions, such as confusional states. The drug is also officially documented to inhibit the Cytochrome P450 enzyme system, a mechanism noted in the safety text that can alter the systemic exposure of certain co-administered medicines.

Overdose and Emergency Response

Documented Overdose Presentations and Risks

The regulatory documentation for Banish (Cimetidine) describes specific clinical manifestations and mandated emergency procedures for overdose.

Domain Official Regulatory Statement
CNS Manifestations Potential for reversible confusional states, agitation, disorientation, psychosis, or hallucinations. These effects are reported primarily in severely ill patients.
Cardiovascular Effects Rare but documented effects associated with the drug class include bradycardia, tachycardia, and A-V heart block.
High-Risk Populations Elderly patients and those with pre-existing kidney or liver problems are at increased risk for CNS toxicity, necessitating careful monitoring.

Required Emergency Actions

In the event of a suspected overdose, official regulatory statements mandate that the patient seek immediate medical attention and contact a Poison Control Center right away.

Management is focused on symptomatic and supportive treatment, as regulatory information confirms that no specific antidote is available. This supportive care includes ensuring the maintenance of the airway and cardiovascular status. Close monitoring is required during management, specifically including the evaluation of renal function for high-risk individuals.

Therapeutic Uses of Banish

What Banish Treats: Main Uses and Benefits

Banish is applied across domains where additional symptomatic support is needed. It is used in situations involving certain distressing symptoms associated with a wide range of conditions involving episodic or fluctuating manifestations.

Banish may assist with common symptom clusters that become intense or disruptive, such as headaches, toothache, muscular aches, backache, and period pain. The medication supports comfort when dealing with symptoms related to inflammatory or irritative states and systemic imbalance. The use of Banish is also relevant for easing symptoms related to systemic imbalance, such as fever.

Banish is relevant for easing symptoms in contexts involving heightened systemic burden, including both acute episodes and chronic conditions.

“This approach contributes to improved comfort during periods of heightened symptoms.”

It provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability.

Quick Fact: Supports ease of Physical Discomfort and Inflammatory States

Regulatory References

  1. Banish (Ibuprofen) Monograph for Oral Use

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Banish — Official Regulatory Information

The eligibility for using Banish (Cimetidine) is defined by governmental regulatory documents, which establish specific rules for patient populations. This information outlines who is permitted to use the medicine and who is formally restricted or excluded.

Eligibility Scope Official Regulatory Status
Populations for whom use is allowed Adults and Children 12 years old.
Populations for whom use is contraindicated Patients with known hypersensitivity to Cimetidine or any component of the formulation (an absolute prohibition).
Age-related eligibility rules Use in Children < 2 years old is officially documented as not fully evaluated or established.
Condition-specific eligibility rules Patients with Impaired Renal Function require a mandatory dose reduction due to the risk of drug accumulation. Caution is advised for those with Impaired Hepatic Function.
Pregnancy and lactation eligibility status Use during Pregnancy is restricted, permitted only if the potential benefit outweighs the risk, as the drug crosses the placenta. Use during Breastfeeding is generally not recommended as the drug is secreted into breast milk.

Eligibility-Context Constraints:

Official labeling imposes constraints primarily based on the risk of drug accumulation in patients with compromised organ function (kidney/liver) and the lack of established safety data in certain vulnerable groups (infants, pregnancy, and lactation). These official statements dictate eligibility status, creating a formal structure for its use.

What should I know about interactions with other medicines?

The official interaction profile of Banish (Cimetidine) is characterized by documented pharmacokinetic inhibition, which significantly alters the systemic exposure of co-administered medicines. Banish is a documented inhibitor of multiple CYP450 enzymes (including CYP1A2, CYP2C9, CYP2D6, and CYP3A4), a mechanism that officially increases the plasma concentration (AUC/Cmax) of various substrates, such as Warfarin, Phenytoin, and Theophylline. Clearance of substances like Metformin and Procainamide is also reduced through competition for renal tubular secretion pathways.

Due to the risk of severe toxicity from increased exposure, co-administration with substances including Dofetilide, Pimozide, Eliglustat, Fezolinetant, and Lomitapide is formally classified as contraindicated in regulatory labeling.

The pH-elevating effect of Banish necessitates mandatory timing rules for certain acid-sensitive medications. For example, drugs like Atazanavir and Ketoconazole must be separated by specific time intervals from Banish administration to maintain their absorption.

Special interaction considerations are officially noted for specific patient groups: the risk of interaction-related reversible confusional states is documented to be heightened in elderly patients and those with renal or hepatic impairment due to reduced drug clearance. Additionally, Antacids should not be taken simultaneously with Banish, and long-term use is associated with impaired Vitamin B12 absorption.

Mechanism of Action

️ How Banish Works

The action of Banish (Cimetidine) is a precise intervention in the physiological cascade that controls gastric acid secretion. Its mechanism is defined by targeted molecular and cellular blockade, resulting in the modulation of the concentration of hydrochloric acid in the gastric fluid.

Targeting the Histamine H2 Receptor

Banish exerts its primary action by engaging in competitive antagonism at the Histamine H2 Receptors located on the acid-producing parietal cells in the stomach lining. This mechanism involves the suppression of the activity of the histamine signaling system, which is a key driver of gastric acid production.

Inhibition of the cAMP Signaling Cascade

By blocking the H2 receptor, Banish interrupts the downstream second-messenger signaling within the cell, specifically preventing the activation of Adenylate Cyclase. This suppression lowers the intracellular concentration of cAMP, thereby diminishing the stimulus that activates the final Proton Pump responsible for secreting hydrogen ions ( H^+).

Resulting Suppression of Gastric Fluid Acidity

The successful interruption of this cascade at the receptor level leads directly to the core physiological effect: reduction in the volume and concentration of hydrogen ions in the gastric fluid. This mechanism primarily influences processes driven by histamine-mediated secretion, though it does not neutralize existing acid or block non-histaminic acid production pathways.

Dosage and Administration Information

Banish (Cimetidine) is administered through multiple routes, including oral dosage forms (tablets and solutions), as well as intravenous (IV) and intramuscular (IM) injections, allowing for its use in both outpatient and acute care settings. Usage follows specific, fixed dosage patterns. For acute management, prescribed regimens often specify 300 mg taken four times a day, typically coordinated with meals and at bedtime, or a simplified dose of 800 mg taken once daily at bedtime. The maximum total daily dose for specialized hypersecretory conditions is defined up to 2400 mg.

The duration of use is defined based on the condition being addressed. Acute treatment courses are generally limited to four to eight weeks. Maintenance therapy may be continued for periods up to five years, while over-the-counter use is limited to continuous self-administration for a maximum of 14 days. Administration includes specific procedural constraints: The injectable solution must be appropriately diluted before IV use and administered over a period of not less than five minutes. Furthermore, dose reduction is utilized for individuals with known renal impairment, where creatinine clearance is below 50 mL/minute, requiring a shift to a lower frequency regimen. When taken with antacids, administration is separated by approximately two hours to prevent absorption interference.

Recent Clinical Evidence

Research evidence / Overview of Studies for Banish (Cimetidine)


Evidence for Use in Healing Peptic Ulcers

Research exploring Banish's evaluation for ulcers primarily involves short-term, randomized controlled trials (RCTs) conducted in adult populations with confirmed duodenal and benign gastric ulcers. The key outcomes measured included the ulcer healing rate, often confirmed by endoscopy, and patient-reported outcomes describing perceived discomfort. Findings described patterns related to the reporting of pain relief in the observed populations. A primary limitation is that much of this original evidence predates the establishment of the association between H. pylori infection and ulcer development, meaning the research does not directly address its role alongside modern treatment protocols aimed at eliminating this bacteria.


Evidence for Management of GERD and Heartburn Symptoms

The evaluation of Banish concerning symptoms of Gastroesophageal Reflux Disease (GERD) and heartburn has been conducted in controlled clinical trials, typically lasting up to 12 weeks. Research examined short-term symptom changes in adult populations, monitoring outcomes related to physical discomfort, such as the frequency of heartburn episodes. Evidence suggests a potential difference between the extent of reported symptomatic relief and the degree of objective tissue healing in some severe cases. The evidence provides limited insight into the comparison with newer categories of acid-suppressing agents.


Long-Term Studies and Ulcer Recurrence Prophylaxis

Research has been conducted on the long-term evaluation of Banish for preventing ulcer recurrence. These maintenance trials focused on the ulcer recurrence rate over follow-up durations extending for six months to over one year. Studies reported differences in the frequency of ulcer relapse during the period of administration. Data described patterns related to ulcer recurrence once the therapy evaluation was completed, indicating that the use for maintenance was studied only during the period of administration.


What is Still Uncertain About Banish Research

Several areas remain limited within the research evidence. Long-term effects are not fully established, particularly regarding the need for maintenance therapy extending beyond the standard trial periods. Evidence quality varies across studies, especially older ones, and the findings describe group patterns, not personal outcomes. Research does not predict whether an individual will respond similarly due to genetic or environmental factors.

Frequently Asked Questions (FAQ)

Common questions about Banish (FAQ)

Q: Why did my doctor prescribe Banish instead of other options?

Official documents classify Banish (Cimetidine) as an established Histamine H2 receptor antagonist. This mechanism is known to block a key signal for gastric acid secretion. The medication is officially indicated for conditions like active ulcers, erosive gastroesophageal reflux disease (GERD), and certain hypersecretory conditions.

Q: Can Banish cause [specific but common side effect, e.g., drowsiness]?

Official labeling reports central nervous system (CNS) side effects, including confusion, dizziness, and headaches. Since CNS effects are documented, the potential for impaired alertness is described in official documentation. This means the drug can potentially affect mental clarity.

Q: Is it normal to feel [general feeling, e.g., slightly nauseous] when first starting Banish?

While specific mention of nausea may not appear among the most common adverse reactions, other mild gastrointestinal issues, such as diarrhea, are commonly reported in regulatory documents. It is officially documented that most side effects tend to be mild and temporary in nature.

Q: Does Banish interact with over-the-counter pain relievers?

Regulatory information indicates that the active ingredient, Cimetidine, can inhibit certain liver enzymes known as CYP450. This can affect the body's processing and clearance of various co-administered drugs. This mechanism means that some non-steroidal anti-inflammatory drugs (NSAIDs) may be affected by these enzyme interactions.

Q: Are there any specific foods or supplements to avoid while taking Banish?

Official product information states that antacids should be taken approximately two hours apart from Banish to prevent absorption interference. Additionally, long-term use has been officially associated with impaired absorption of Vitamin B12. No specific dietary foods are broadly prohibited in regulatory documents.

Q: Can Banish be used by older adults?

Banish is approved for use in the adult population. However, regulatory warnings note that elderly patients have a documented increased risk for central nervous system (CNS) adverse reactions, such as confusion. This increased risk is associated with documented changes in drug clearance in this population.

Q: Does Banish need a special prescription?

Banish is available in lower strengths as an over-the-counter (OTC) medicine for treating heartburn. However, higher strengths and use for long-term or severe conditions typically require a prescription. The regulatory status depends on the specific strength and indication.

Q: Is Banish safe to take before driving or operating machinery?

Official warnings list side effects that can affect the central nervous system, such as dizziness and confusion. These effects have the potential to impair a person's judgment and motor skills. Regulatory documents note that the presence of CNS adverse reactions can affect the ability to perform activities like driving or operating machinery.

Q: Can Banish be taken on an empty stomach?

Official acute dosing regimens often suggest coordinating administration with meals and at bedtime to optimize the drug's effect on acid production. Administration coordinated with meals is described in official dosing regimens for managing its effects. Specific regulatory documents do not strictly prohibit taking it on an empty stomach.

Q: How is Banish eliminated from the body?

Regulatory pharmacokinetics information describes Banish (Cimetidine) as being primarily eliminated from the body by the kidneys. This process is known as renal excretion. For this reason, official instructions include a mandatory dose adjustment consideration for individuals with known kidney problems.

Q: Can Banish affect the results of common laboratory tests?

Yes, regulatory labeling reports that Banish can cause a reversible increase in the plasma creatinine concentration. This is a common lab test used to assess kidney function. This change is typically observed during the first week of treatment.

Q: Does Banish require special monitoring or follow-up tests?

Mandatory dose reduction is officially required for patients with known kidney impairment, which requires consideration of kidney function monitoring. Furthermore, the drug's documented effect on B12 absorption during long-term use implies a potential need for nutritional follow-up.

Q: Can Banish affect my sleep pattern?

Banish is often administered once daily at bedtime to target nocturnal acid secretion. While the official adverse reaction lists report CNS effects like confusion and headaches, which can indirectly affect rest, official documents do not commonly list insomnia as a frequent side effect.

Q: Does Banish start working right away?

Regulatory studies show that Banish begins to suppress stomach acid secretion shortly after it is administered. A single dose can significantly reduce acid activity within the first few hours of administration, particularly targeting the acid produced at night.

Q: How long does it typically take to notice the described effects of Banish?

Clinical trials for conditions like duodenal ulcers have reported that pain relief can begin rapidly, with some individuals experiencing relief from nighttime pain after just one day of treatment. Complete healing of ulcers, however, typically requires a full course of therapy lasting several weeks.

Q: Is Banish affected by drinking alcohol?

Regulatory-related documents indicate that Cimetidine may inhibit the body's breakdown of alcohol. This could potentially increase alcohol's effects and heighten the risk of related side effects, such as dizziness or drowsiness, as noted in the drug's safety profile.

Q: Is Banish available as a generic medicine?

Yes, the active ingredient in Banish, Cimetidine, is available as a generic medicine. The generic version has met the necessary regulatory standards to be considered equivalent to the branded product.

Q: Is Banish a controlled substance?

No, Cimetidine (Banish) is not classified as a controlled substance. This classification is reserved by regulatory bodies for medicines with potential for abuse or dependence.

Q: Why is Banish sometimes prescribed in combination with other treatments?

Regulatory-cited guidelines indicate that Banish is sometimes prescribed alongside anti-infective therapy for patients with documented ulcers related to extitH. pylori infection. The combination is intended to both suppress acid and help eliminate the bacteria.

Q: Is Banish a habit-forming or addictive medicine?

Official documents do not characterize Banish (Cimetidine) as a habit-forming or addictive medicine. The regulatory category for drugs with potential for abuse or dependence does not include this medication.

How should Banish be stored and disposed of?

How to Store and Dispose of Banish

Banish (Cimetidine) must be stored according to specific regulatory requirements to ensure stability. Tablets must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), while avoiding excessive heat and freezing. The medication requires protection from light and moisture and must be stored in a tightly closed, light-resistant container.

Stability and Handling

Item Rule
Oral Solution Discard after one month from opening
Container Rule Keep out of the reach and sight of children

Disposal of unused or expired Banish must be done in accordance with local and national pharmaceutical waste regulations. The product should not be disposed of in household wastewater or poured into drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Banish found in:

A-Z Index: